Table 1.
Population description.
| PHASE I AND II SAMPLE | PHASE III SAMPLE | ||||||
|---|---|---|---|---|---|---|---|
| Controls | AD | Controls | AD | Othera | |||
| n= | 21 | 21 | p Value | 3 | 3 | 6 | p Value |
| Age mean (SD) | 87 (5.59) | 81.4 (7.24) | 0.008 | 86 (13.9) | 72 (13.0) | 69.17 (12.0) | 0.095 |
| APOE ε4 | |||||||
| ε4+ | 4 | 14 | 1 | 3 | 3 | ||
| ε4− | 17 | 7 | 0.002 | 2 | 0 | 3 | 0.875 |
| Gender | |||||||
| Males | 11 | 10 | 0 | 3 | 5 | ||
| Females | 10 | 11 | 0.758 | 3 | 0 | 1 | 0.025 |
| Braak stage | |||||||
| 0 | 0 | 0 | 0 | 0 | 1 | ||
| I | 4 | 0 | 0 | 0 | 0 | ||
| II | 10 | 0 | 0 | 0 | 2 | ||
| III | 6 | 0 | 3 | 0 | 1 | ||
| IV | 1 | 2 | 0 | 0 | 1 | ||
| V | 0 | 5 | 0 | 1 | 1 | ||
| VI | 0 | 14 | <0.0001 | 0 | 2 | 0 | 0.521 |
| Neuritic plaque score | |||||||
| Absent | 6 | 0 | 1 | 0 | 1 | ||
| Sparse | 10 | 0 | 2 | 0 | 2 | ||
| Moderate | 5 | 6 | 0 | 0 | 0 | ||
| Frequent | 0 | 5 | <0.0001 | 0 | 3 | 3 | 0.397 |
| Post-mortem interval | |||||||
| Mean | 4.7 | 5.1 | 0.453 | 4.9 | 5.2 | 4.5 | 0.756 |
| Minimum | 2.3 | 2.2 | 3.3 | 3.5 | 3.0 | ||
| Maximum | 7.3 | 8.3 | 6.0 | 8.0 | 9.3 | ||
| RNA 260/280; mean (SD) | |||||||
| Cerebellum | 2.05 (0.068) | 2.06 (0.189) | 0.921 | 2.04 (0.10) | 2.04 (0.23) | 2.07 (0.12) | 0.7218 |
| Hippocampus | 2.06 (0.117) | 2.08 (0.216) | 0.717 | 2.03 (0.04) | 2.00 (0.00) | 2.01(0.07) | 0.7518 |
| Cerebrospinal Fluid | – | – | 2.83 (1.89) | 2.00 (0.00) | 2.17 (0.47) | 0.5707 | |
| Plasma | – | – | 2.00 (0.00) | 2.00 (0.00) | 2.50 (1.00) | 0.5328 | |
a
Lewy body variant AD (n=2), dementia with Lewy bodies (n=1), frontaltemporal dementia (n=2), Parkinson’s disease dementia (n=1).